Robyn Karnauskas
Stock Analyst at Truist Securities
(3.27)
# 987
Out of 4,650 analysts
178
Total ratings
46.1%
Success rate
2.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Downgrades: Hold | $320 → $333 | $316.00 | +5.38% | 11 | Oct 14, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $143 → $132 | $103.73 | +27.25% | 9 | Oct 9, 2024 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $88.08 | -5.77% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $189.45 | +10.85% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $12.06 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $183.47 | +85.32% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $4.63 | +461.56% | 2 | May 15, 2024 | |
| CHRS Coherus BioSciences | Maintains: Buy | $8 → $7 | $0.74 | +841.62% | 13 | May 13, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,135 | $927.33 | +22.39% | 16 | Apr 3, 2024 | |
| OABI OmniAb | Maintains: Buy | $10 | $3.94 | +153.81% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $4.17 | +115.83% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $27.10 | +173.06% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.58 | +98.62% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $29.88 | +60.64% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $16.41 | +204.69% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $903.58 | -5.93% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $470.36 | +8.00% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $28.46 | +26.49% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $52.50 | +60.00% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $42.50 | -41.18% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.71 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $69.91 | +100.26% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $1.75 | +8,471.43% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $2.72 | +157.35% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $6.42 | +756.70% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $3.17 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $2.83 | +924.73% | 1 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $34.41 | +829.96% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $3.93 | +281.68% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.58 | +445.85% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $8.75 | +871.43% | 1 | Oct 8, 2020 |
Amgen
Oct 14, 2024
Downgrades: Hold
Price Target: $320 → $333
Current: $316.00
Upside: +5.38%
Merck & Co.
Oct 9, 2024
Maintains: Buy
Price Target: $143 → $132
Current: $103.73
Upside: +27.25%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $88.08
Upside: -5.77%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $189.45
Upside: +10.85%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $12.06
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $183.47
Upside: +85.32%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $4.63
Upside: +461.56%
Coherus BioSciences
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.74
Upside: +841.62%
Regeneron Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $927.33
Upside: +22.39%
OmniAb
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $3.94
Upside: +153.81%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $4.17
Upside: +115.83%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $27.10
Upside: +173.06%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.58
Upside: +98.62%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $29.88
Upside: +60.64%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $16.41
Upside: +204.69%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $903.58
Upside: -5.93%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $470.36
Upside: +8.00%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $28.46
Upside: +26.49%
Oct 6, 2023
Reiterates: Buy
Price Target: $84
Current: $52.50
Upside: +60.00%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $42.50
Upside: -41.18%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.71
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $69.91
Upside: +100.26%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $1.75
Upside: +8,471.43%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $2.72
Upside: +157.35%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $6.42
Upside: +756.70%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $3.17
Upside: -
Nov 16, 2022
Initiates: Buy
Price Target: $29
Current: $2.83
Upside: +924.73%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $34.41
Upside: +829.96%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.93
Upside: +281.68%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $4.58
Upside: +445.85%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $8.75
Upside: +871.43%